Form D · Biotechnology
Oncofactor Corp
Seattle, WA · CIK 0001520541
Offering snapshot reported Sep 3, 2013 · SEC filing
- Reported sold
- $1M Offering amount: $6M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 22, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2013 | Initial | $1,000,000 | No comparison | 5 | SEC filing |
| May 19, 2011 | Initial | $2,100,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-202194
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Sep 3, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lee Babiss | Director |
| Steve Gillis | Director |
| Thong Le | Director |
| David Mc Elligott | Executive |
| Janis Naeve | Director |
| Lindsay Rayle | Executive |
| David Schubert | Executive |
| Chad Waite | Director |
| Carl Weissman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Ave E, Suite 200
Seattle, WA, 98102
Seattle, WA, 98102